Showing 6511-6520 of 8885 results for "".
- Derm Students Improve Wikipedia Entries on Skin Disease, Boost Viewshttps://practicaldermatology.com/news/derm-students-improve-wikipedia-entries-on-skin-disease-boost-views-1/2459992/A group of medical students recruited to improve Wikipedia articles on skin-related diseases and saw millions more views of those stories following their editing, a new study shows. "We tried to make the articles more readable, while adding more relevant information," say
- Encore Dermatology Acquires Marketing Rights to Promius Pharma Brandshttps://practicaldermatology.com/news/encore-dermatology-acquires-marketing-rights-to-promius-pharma-brands-1/2459989/Encore Dermatology is purchasing the US rights to market Sernivo® (betamethasone dipropionate) Spray, 0.05% and is being assigned the rights to market and distribute Promiseb® Topical Cream and Trianex® 0.05% (Triamcinolone Acetonide Ointment, USP) from Dr. Reddy’
- PALLAS Ti: Sapphire Solid State Laser Shows Similar Efficacy and Safety to 308nm Excimer Laser for Localized Vitiligohttps://practicaldermatology.com/news/pallas-tisapphire-solid-state-laser-shows-similar-efficacy-and-safety-to-308nm-excimer-laser-for-localized-vitiligo/2459953/A novel 311nm Titanium:Sapphire UV laser demonstrates comparable efficacy and safety when compared to 308nm excimer laser in the treatment of localized vitiligo, according to a study recently published in Lasers in Surgery and Medicine. Manufactured by
- BTL to Launch Small Emsculpt Applicator for Arms, Thighs, Calveshttps://practicaldermatology.com/news/btl-to-launch-small-emsculpt-applicator-for-arms-thighs-calves/2459955/BTL is rolling out a small Emsculpt applicator to treat arms, thighs and calves at the annual meeting of the American Society for Laser Medicine and Surgery in Denver. Until now, there were only protocols for the abdominals and buttocks. In addition to launching the small appl
- Allergan Acquires Envy Medical, Inc.https://practicaldermatology.com/news/allergan-acquires-envy-medical-inc/2459957/Allergan now owns Envy Medical, Inc. The acquisition adds Envy's Dermalinfusion, a non-surgical, non-invasive skin resurfacing system for the face and body, to Allergan's portfolio. Offered in physician's offices, medical spas and l
- Biofrontera Acquires Cutanea Life Scienceshttps://practicaldermatology.com/news/biofrontera-acquires-cutanea-life-sciences/2459959/Biofrontera Inc., USA entered into an agreement to acquire all shares in Cutanea Life Sciences, Inc., USA through its subsidiary Biofrontera Newderm LLC as the acquirer, with Maruho Co., Ltd., Japan as the seller. Maruho holds approximately 20 percent of Biofrontera AG. Cutanea is a US-based phar
- Cutera Hosts Beauty Talk with Sadick and Sadickhttps://practicaldermatology.com/news/cuter-hosts-beauty-talk-with-sadick-and-sadick/2459960/Dermatologist Neil Sadick, MD and his daughter Sydney Sadick, an in-the-know fashion journalist, talked about everything from state-of-the-art skin brightening treatments to the newest injectables and how to get svelte without sweating or surgery at
- CoolSculpting and Sonja Morgan Partner to Talk Bikini Denialhttps://practicaldermatology.com/news/coolsculpting-and-sonja-morgan-partner-to-talk-bikini-denial/2459963/Star of Bravo's "The Real Housewives of New York City" Sonja Morgan is opening up about her ‘Bikini Denial’ as part of her partnership with CoolSculpting. Bikini Denial is the feeling that many woman get when realizing that swimsuit season has snuck up on her and
- Are Skin Diseases More Common Than Previously Held?https://practicaldermatology.com/news/are-skin-diseases-more-common-than-previously-held/2459964/Skin diseases may be more common than previously believed, according to a new study in the Journal of the European Academy of Dermatology and Venereology that estimates the prevalence of skin diseases outside of the
- Dermira's Investigational AD Drug Performs Well in Phase 2b Trial, Shares Skyrockethttps://practicaldermatology.com/news/ready-for-phase-3-dermiras-investigational-ad-drug-performs-well-in-phase-2b-trial/2459969/All three doses of Dermira, Inc.’s lebrikizumab showed greater improvements in the Eczema Area and Severity Index in a new Phase 2b dose-ranging study of adults with moderate-to-severe atopic dermatitis, and shares of D